Abstracts tagged "Inflammasome"

Abstract Number: 1010 • ACR Convergence 2021
Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease
Paul Tsoukas¹, Melissa Kleinau², Lysa Langevin², Lily Morikawa³, Trang Duong¹, Suzanne Tam⁴ and Rae Yeung⁵, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, ⁴Hospital for Sick Children, Toronto, ON, ⁵The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Kawasaki disease (KD), is the leading cause of acquired heart disease in childhood. Up to 20% of patients may develop coronary artery lesions (CAL)…
Abstract Number: 1110 • ACR Convergence 2021
Cryopyrin-associated Periodic Syndromes: GOSH and National Amyloidosis Centre Experience
Ovgu Kul Cinar¹, Charalampia Papadopoulou², Amber Putland¹, Karen Wynne¹, Helen J Lachmann³, Despina Eleftheriou⁴ and Paul A. Brogan⁴, ¹Great Ormond Street Hospital NHS Trust, London, United Kingdom, ²UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology, London, United Kingdom, ³National Amyloidosis Centre, Royal Free Campus, UCL Medical School, London, United Kingdom, ⁴Great Ormond Street Hospital NHS Trust, UCL GOS Institute of Child Health, Department of Infection, Immunity & Inflammation, London, United Kingdom
Background/Purpose: CAPS is a rare, heterogenous inflammasomopathy associated with gain-of-function mutations in NLRP3 that encodes cryopyrin. Mutations in NLRP3 result in excessive IL-1ß production that…
Abstract Number: 1578 • ACR Convergence 2021
NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status
MARIANO ANDRES¹, Leticia Mendieta², Elena Argente-delcastillo¹, Miguel Trigueros³ and Alberto Miñano³, ¹Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ²Universidad Miguel Hernández, San Juan de Alicante, Spain, ³Hospital General Universitario de Alicante-ISABIAL, Alicante
Background/Purpose: Both hyperuricemia and monosodium urate crystals induce persistent inflammation. In vitro, soluble urate can prime innate immune cells and promote NLRP3 inflammasome activation and…
Abstract Number: 0063 • ACR Convergence 2020
Novel Repurposed Drugs Against Joint Inflammation Reveal Potential Use for Gout Treatment: An In Silico, In Vitro and Clinical Study
Eloi Franco-Trepat¹, Ana Alonso-Pérez¹, Maria Guillán-Fresco¹, Miriam López-Fagundez¹, Andrés Pazos-Pérez¹, Ana Lois Iglesias², Susana Belén Bravo³, Alberto Jorge-Mora¹, JJ Gómez-Reino⁴ and Rodolfo Gómez¹, ¹IDIS-CHUS - Musculoskeletal Pathology Group, Santiago de Compostela, Spain, ²IDIS-CHUS - Musculoskeletal Pathology Group, A Coruna, Spain, ³IDIS-CHUS - Proteomics Unit, Santiago de Compostela, Galicia, Spain, ⁴IDIS-CHUS - Rheumatology Group, Santiago de Compostela, Spain
Background/Purpose: Joint inflammation is a common feature across multiple rheumatic diseases. To deal with the induction of innate immune factors, targeting therapeutic targets such as…
Abstract Number: 1163 • ACR Convergence 2020
Predictors of Colchicine Response in Patients with Undefined Systemic Autoinflammatory Diseases
Mariana Correia Marques¹, Edwin Anderson¹, Kathryn Williams², Jonathan Hausmann³ and Fatma Dedeoglu⁴, ¹Boston Children`s Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA, ²Biostatistics and Research Design Center ICCTR Boston Children`s Hospital, Boston, MA, ³Boston Children’s Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ⁴Boston Children's Hospital, Boston, MA
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) result from dysregulation of the innate immune system. Many patients with SAIDs have specific mutations that lead to the release…
Abstract Number: 1911 • ACR Convergence 2020
IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1
Caya McFalls¹ and Carol Artlett¹, ¹Drexel University College of Medicine, Philadelphia
Background/Purpose: Interleukin-11 (IL-11) has been shown to be associated with idiopathic pulmonary fibrosis, cardiac and kidney fibrosis. However, conflicting data shows IL-11 can be either…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].